Last reviewed · How we verify

Fluorescent stain — Treatment Landscape & Competitive Intelligence

Fluorescent stain (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Fluorescent stain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Levulan AMINOLEVULINIC ACID Sun Pharma Optical Imaging Agent 1999-01-01
Ameluz Ameluz Sherrif Ibrahim
Gliolan Gliolan Abramson Cancer Center at Penn Medicine

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Abramson Cancer Center at Penn Medicine · 1 drug in Fluorescent stain
  2. Sherrif Ibrahim · 1 drug in Fluorescent stain
  3. Sun Pharma · 1 drug in Fluorescent stain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Fluorescent stain:

Cite this brief

Drug Landscape (2026). Fluorescent stain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/fluorescent-stain. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing